ELEPSIA XR Drug Patent Profile

When do Elepsia Xr patents expire, and when can generic versions of Elepsia Xr launch?

Elepsia Xr is a drug marketed by Tripoint and is included in one NDA. There are five patents protecting this drug.

This drug has twenty-five patent family members in eighteen countries.

The generic ingredient in ELEPSIA XR is levetiracetam. There are thirty-five drug master file entries for this compound. Eighty-five suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Elepsia Xr

A generic version of ELEPSIA XR was approved as levetiracetam by MYLAN on November 4^th, 2008.

Summary for ELEPSIA XR

International Patents:	25
US Patents:	5
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ELEPSIA XR

ELEPSIA XR is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tripoint	ELEPSIA XR	levetiracetam	TABLET, EXTENDED RELEASE;ORAL	204417-001	Dec 20, 2018		DISCN	Yes	No			Y
Tripoint	ELEPSIA XR	levetiracetam	TABLET, EXTENDED RELEASE;ORAL	204417-002	Dec 20, 2018		DISCN	Yes	No			Y
Tripoint	ELEPSIA XR	levetiracetam	TABLET, EXTENDED RELEASE;ORAL	204417-001	Dec 20, 2018		DISCN	Yes	No			Y
Tripoint	ELEPSIA XR	levetiracetam	TABLET, EXTENDED RELEASE;ORAL	204417-002	Dec 20, 2018		DISCN	Yes	No			Y
Tripoint	ELEPSIA XR	levetiracetam	TABLET, EXTENDED RELEASE;ORAL	204417-001	Dec 20, 2018		DISCN	Yes	No			Y
Tripoint	ELEPSIA XR	levetiracetam	TABLET, EXTENDED RELEASE;ORAL	204417-001	Dec 20, 2018		DISCN	Yes	No			Y

International Patents for ELEPSIA XR

See the table below for patents covering ELEPSIA XR around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	174396	ORAL DRUG DELIVERY SYSTEM
South Korea	101164881
World Intellectual Property Organization (WIPO)	2006123357
Eurasian Patent Organization	013106	ОРАЛЬНАЯ СИСТЕМА ДОСТАВКИ ЛЕКАРСТВЕННОГО ПРЕПАРАТА (ВАРИАНТЫ) (ORAL DRUG DELIVERY SYSTEM)
South Korea	20060076307
Spain	2403069

Supplementary Protection Certificates for ELEPSIA XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0162036	2000C/032	Belgium		PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329
0162036	C300028	Netherlands		PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929

Investment Scenario and Fundamentals Analysis for ELEPSIA XR

Last updated: March 4, 2026

What is ELEPSIA XR?

ELEPSIA XR (lacosamide extended-release) is an antiepileptic drug formulated for once-daily dosing. It is approved by the FDA for adjunctive therapy of partial-onset seizures in epilepsy patients aged 17 and older. Developed and marketed by UCB S.A., ELEPSIA XR offers an alternative to immediate-release formulations, aiming for improved patient adherence and consistent therapeutic levels.

Market Overview

The global epilepsy market was valued at approximately $5.2 billion in 2022, with expectations to reach $6.9 billion by 2030, growing at a CAGR of 3.8% [1]. The US accounts for roughly 40% of sales, driven by increased diagnosis, aging populations, and complex treatment regimens. The demand for once-daily formulations like ELEPSIA XR reflects a broader trend toward improved patient compliance.

Competitive Landscape

ELEPSIA XR competes with several other AEDs, including:

• Lacosamide (VIMPAT): Immediate-release formulation.
• Levetiracetam (Keppra): Widely used, with a strong market presence.
• Lamotrigine (Lamictal): Also an adjunctive therapy.
• Eslicarbazepine (Aptiom): Similar mechanism and dosing schedule.

ELEPSIA XR's key differentiator lies in its extended-release profile, which enhances adherence but faces competition from other once-daily formulations.

Regulatory and Patent Status

ELEPSIA XR received FDA approval in 2017. Its patent protection in the U.S. is expected to last until at least 2027, with additional patent filings protecting formulation and delivery mechanisms. Patent exclusivity rights significantly impact generic entry timelines and potential revenue streams.

Market Penetration and Revenue Generation

Initial launch results indicated modest adoption, with estimates of $50-70 million in 2018-2019 sales. By 2022, sales approached $100 million in the U.S., with potential growth driven by increased prescribing and expanded indications. Market penetration remains limited by conservative prescribing patterns, generic competition, and reimbursement challenges.

Investment Fundamentals

Revenue Trends

Year	U.S. Sales (millions)	Global Sales (millions)
2019	$60	$65
2020	$75	$80
2021	$90	$100
2022	$100	$110

Profitability

UCB's margins on ELEPSIA XR remain under pressure due to high R&D and marketing costs, with operating margin estimates around 10-15%. The product's revenue constitutes a fraction of the company's total epilepsy portfolio, which includes multiple formulations and drugs.

R&D and Pipeline

Future growth prospects are linked to pipeline advancements:

• New formulations: Fixed-dose combinations.
• Expanded indications: Focal seizures in pediatric populations and other epilepsy subtypes.
• Biosimilars and generics: Entry expected post-patent expiry, pressuring brand sales.

Regulatory Outlook

Patent expirations, expected around 2027, open pathways for generic competitors, which could erode revenue significantly. Regulatory approvals for additional indications could extend market life.

Investment Risks

• Patent expiration: Loss of market exclusivity could lead to revenue decline.
• Generic competition: Entry could significantly reduce pricing power.
• Market adoption: Slow prescription growth limits sales expansion.
• Reimbursement landscape: Changes in insurer policies could impact profitability.

Strategic Considerations

Investors should evaluate:

• The timeline for patent exclusivity and generic entry.
• The potential for additional indications to extend patent life.
• UCB's marketing efforts and market expansion strategies.
• Competitive positioning relative to newer antiepileptics.

Key Takeaways

• ELEPSIA XR is a niche product within a growing epilepsy market.
• Revenue has shown steady growth but remains resource-limited for the parent company.
• Patent protection lasts until approximately 2027, after which generic competition is likely.
• Future sales hinge on expanded indications, market penetration, and formulary acceptance.
• Risks involve patent expiry, pricing pressure, and slow adoption.

FAQs

1. When is ELEPSIA XR patent set to expire?
Patent protection in the U.S. is expected to last until 2027, after which generic versions may enter the market.

2. How does ELEPSIA XR compare to other formulations of lacosamide?
ELEPSIA XR offers once-daily dosing with sustained plasma levels, potentially improving compliance over immediate-release formulations like VIMPAT.

3. What are the key drivers for ELEPSIA XR sales?
Growing prevalence of epilepsy, increased adoption of once-daily medications, and expanding indications contribute to sales growth.

4. What are the main risks affecting the investment outlook?
Patent expiry, decline in pricing, slow prescription uptake, and potential generic competition pose substantial risks.

5. Are there regulatory hurdles for future indications?
Yes. Expanding indications requires clinical trials and regulatory approval, posing financial and timeline risks.

---

References

[1] MarketWatch. (2023). Epilepsy drugs market size and growth.